P-Xylene

P-Xylene

SCHEMBL497786

Cc1ccc(C)cc1.[B+3].[Cl-].[Cl-].[Cl-]

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of P-Xylene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 6/20 0.80
TDP1 Q9NUW8 1/20 0.80
ALDH1A1 P00352 4/20 0.53
CA2 P00918 2/20 0.53
CA1 P00915 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
TSHR P16473 3/20 0.50
LMNA P02545 2/20 0.50
ALOX12 P18054 1/20 0.50
CYP2A6 P11509 3/20 0.44
IDO1 P14902 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
LPL P06858 1/20 0.44
LIPG Q9Y5X9 1/20 0.44
ORAI1 Q96D31 1/20 0.44
ORAI2 Q96SN7 1/20 0.44
ORAI3 Q9BRQ5 1/20 0.44
TRPV6 Q9H1D0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
P-Xylene SCHEMBL11770184 0.89 ACHE (1.00) ACHETDP1ALDH1A1CA2CA1
P-Xylene SCHEMBL11772917 0.89 ACHE (1.00) ACHETDP1ALDH1A1CA2CA1
P-Xylene SCHEMBL771 0.89
P-Xylene SCHEMBL460348 0.89 ACHE (1.00) ACHETDP1ALDH1A1CA2CA1
P-Xylene SCHEMBL11003481 0.84
P-Xylene SCHEMBL1508153 0.84 ACHE (0.89) ACHETDP1ALDH1A1CA2CA1
P-Xylene SCHEMBL21270023 0.84
P-Xylene SCHEMBL20873607 0.84
P-Xylene SCHEMBL461064 0.84 ACHE (0.89) ACHETDP1ALDH1A1CA2CA1
P-Xylene SCHEMBL3847044 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8105431-B2 Subphthalocyanine derivative having phosphorus derivative as axially substituted group, method for manufacturing the same and optical film using the same ORIENT CHEMICAL INDUSTRIES, LTD. (JP) 2012-01-31 US disclosed
EP-2184328-B1 Subphthalocyanine derivative having phosphorus derivative as axially substituted group, method for manufacturing the same and optical film using the same ORIENT CHEMICAL IND (JP) 2011-04-27 EP disclosed
EP-2184328-A2 Subphthalocyanine derivative having phosphorus derivative as axially substituted group, method for manufacturing the same and optical film using the same Orient Chemical Industries, Ltd. (JP) 2010-05-12 EP disclosed
US-20100036134-A1 Subphthalocyanine derivative having phosphorus derivative as axially substituted group, method for manufacturing the same and optical film using the same ORIENT CHEMICAL INDUSTRIES, LTD. (JP) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036134-A1 Subphthalocyanine derivative having phosphorus derivative as axially substituted group, method for manufacturing the same and optical film using the same PHLPP1, PHLPP2, PROX1 ACHE 2685/4885TDP1 1636/4885ALDH1A1 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.